Frontage provides comprehensive discovery phase, preclinical and clinical bioanalytical laboratory solutions to global markets allowing for the successful development of important therapies and products for patients as quickly as possible.
Full Suite of Bioanalytical Services for Global Customers
Frontage’s experienced bioanalytical scientists support a full suite of services using state-of-the-art instrumentation and software.
- Mass Spectrometry
- Quantification of Small Molecules, Peptides, Oligonucleotides, protein biomarkers, liposomal drugs and therapeutical protein drugs and ADCs
- ICP-MS for elemental (Metals)
- Biologics and Bioassays
- ADC
- Immunogenicity (ADA)
- Biosimilars
- Biomarkers for Precision Medicine
- Genomics
- Gene and Cell Therapy
- Assays
Deep Scientific Expertise:
Our deep scientific expertise allows us to provide clients with customized solutions for challenging studies including oncology clinical trials, rare disease assay development, and specialty assays, such as pediatrics bioanalysis, inhalant drug, liposomal drug, LNP drugs, gene and cell therapy drugs . Our bioanalytical laboratory solutions support every stage of product development and drug discovery for pharmaceuticals and biotechnology companies.
{Infographic} Our bioanalytical team has been developing methods and analyzing bioanalytical samples for more than 20 years to our sponsors globally. We have over 450 scientists in multiple facilities located in the USA, Canada, Europe and China. Our senior scientists average 10 – 15 years in complex drug development and many come from leading Pharmaceutical companies. Over 70% of our scientists hold advanced degrees.
Harmonized Processes:
At Frontage BioA, standardized Standard Operating Procedures (SOPs) and uniform quality standards are rigorously implemented across all our facilities worldwide. Our commitment to consistency extends to our instrumental setup and software systems, which are harmonized throughout our global service network. Additionally, dedicated importation and exportation logistics teams are in place to facilitate seamless method transfers, partial validations, and method cross-validations across different Frontage BioA facilities, supporting global late phase clinical trials.
Quality:
The data generated by Frontage BioA facilities worldwide is suitable for regulatory submission on a global scale, including to regulatory bodies such as the FDA, EMEA, ANVISA, NMPA, WHO, and others.
Frontage Global Facilities with Bioanalytical Services
Frontage has facilities in Exton, PA, Hayward, CA, Vancouver, Canada, Shanghai, China and Suzhou China providing R&D and GLP-compliant, quantitative mass spectrometry services to biotech and pharmaceutical industries, supporting all preclinical and clinical PK / TK / DDI / BA / BE, protein binding, and biomarker studies.
Paperless labs
With the implementation of IEBS (Integrated Electronic Binder System), IDBS electronic notebook system (EWB), Watson LIMS system, Quickbase project management, Employee training module ZenQMS, StudyDoc automatic report generating system, validated Adobe Sign and more, WE take great pride in establishing one of the few bioanalytical laboratories worldwide that has achieved a paperless under GLP environment with LC-mass spectrometry platform. Frontage IT department continues to implement paperless labs to all of our global bioanalytical facilities.